Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine-Reference-Cited by-同舟云学术

Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine

Published:2017-12-09 Issue:1 Volume:109 Page:215-224
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Ikeda Masafumi¹^ORCID,Ioka Tatsuya²,Fukutomi Akira³,Morizane Chigusa⁴,Kasuga Akiyoshi⁵,Takahashi Hideaki¹,Todaka Akiko³,Okusaka Takuji⁴,Creasy Caretha L.⁶,Gorman Shelby⁶,Felitsky Daniel J.⁷,Kobayashi Mikiro⁸,Zhang Fanghong⁸,Furuse Junji⁵^ORCID

Affiliation:

1. Department of Hepatobiliary and Pancreatic Oncology; National Cancer Center Hospital East; Kashiwa Japan

2. Osaka International Cancer Institute; Osaka Japan

3. Shizuoka Cancer Center; Shizuoka Japan

4. National Cancer Center Hospital; Tokyo Japan

5. Department of Medical Oncology; Kyorin University; Tokyo Japan

6. GlaxoSmithKline; Philadelphia PA USA

7. Jounce Therapeutics; Cambridge MA USA

8. Novartis Pharma; Tokyo Japan

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.13438/fullpdf

Reference37 articles.

1. Systemic therapy for biliary tract cancers;Hezel;Oncologist,2008

2. National Cancer Center Cancer statistics in Japan 2009 http://www.fpcr.or.jp/publication/statistics.html

3. Biliary tract cancers: SEOM clinical guidelines;Benavides;Clin Transl Oncol,2015

4. Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations;Marcano-Bonilla;Chin Clin Oncol,2016

5. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N Engl J Med,2010

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting the molecular mechanism-driven progression of breast cancer through comprehensive network pharmacology and molecular docking approach;Scientific Reports;2023-08-22

2. Intrahepatic cholangiocarcinoma: Evolving role of neoadjuvant and targeted therapy;Annals of Hepato-Biliary-Pancreatic Surgery;2023-02-24

3. Establishment of two oxaliplatin-resistant gallbladder cancer cell lines and comprehensive analysis of dysregulated genes;Open Medicine;2023-01-01

4. The Hallmarks of Liver Fluke Related Cholangiocarcinoma: Insight into Drug Target Possibility;Liver Fluke, Opisthorchis viverrini Related Cholangiocarcinoma;2023

5. Targeted Therapy: Molecular Pathology and Targets of Gallbladder Cancer;Gallbladder Cancer;2023